HomeAnalysisLife SciencesOncology BD&L: Winning in an Increasingly Competitive Environment

Oncology BD&L: Winning in an Increasingly Competitive Environment

-

As competition intensifies, success in oncology dealmaking depends on disciplined focus, speed and strategic positioning.

Oncology dominates global biopharma BD&L, with rising deal values and growing innovation from new modalities and geographies. Companies that combine sharp asset targeting with agile execution will secure the best opportunities

Provide your email address to continue reading

For unlimited free access to all articles and analysis from the past month

Or to access 5,700+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Already have an account?
L.E.K Consulting
L.E.K Consultinghttps://www.lek.com/
L.E.K. Consulting is a global strategy consultancy with a dedicated Healthcare and Life Sciences practice. We partner with European investors and operators across provider services, medtech, biopharma and digital health to unlock growth and value. Our work spans origination, commercial and vendor due diligence, value-creation planning (pricing, network and capacity, digital), buy-and-build and integration through to exit readiness. We combine sector expertise with proprietary research and on-the-ground European insight to deliver clear, investable answers — fast.
Related Articles
More From Author

…

Provide your email address to continue reading

For unlimited free access to all articles and analysis from the past month

Or to access 5,700+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Already have an account?

…

Provide your email address to continue reading

For unlimited free access to all articles and analysis from the past month

Or to access 5,700+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Already have an account?
Advertisement

Related Resources

Related Events